Nancy Read
Papers
6
Total Citations
660
H-Index
5
About
Dr. Nancy Read is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate between surgical and non-surgical treatments for oropharyngeal squamous cell carcinoma (OPSCC). Her primary research focus is on optimizing treatment de-escalation for HPV-related oropharyngeal cancer, specifically comparing the functional outcomes and survival between primary radiotherapy and transoral robotic surgery (TORS). Dr. Read is best known as the principal investigator of the landmark ORATOR trial, a phase II randomized study that directly compared these two modalities. The trial’s primary results, published in 2019 and cited over 450 times, provided critical, high-level evidence on swallowing-related quality of life, challenging assumptions about the superiority of one approach over the other. Her subsequent work, including the final five-year outcomes and a detailed swallowing sub-study, continues to provide essential data for clinical decision-making. With a cumulative citation count exceeding 650 for her ORATOR-related publications, Dr. Read’s rigorous, randomized trial methodology has set a new standard for evidence in a field previously dominated by retrospective data, making her a pivotal figure in the modern management of early-stage oropharynx cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6